BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 3374170)

  • 1. Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
    Griffiths SD; Cawley JC
    Leukemia; 1988 Jun; 2(6):377-81. PubMed ID: 3374170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The beneficial effects of alpha-interferon in hairy cell leukemia are not attributable to NK cell-mediated cytotoxicity.
    Griffiths SD; Cawley JC
    Leukemia; 1987 Apr; 1(4):372-6. PubMed ID: 3669763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hairy cell leukemia cells are relatively NK-insensitive targets.
    Starling GC; Nimmo JC; Hart DN
    Pathology; 1988 Oct; 20(4):361-5. PubMed ID: 2977221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism between alpha-interferon and interleukin-2-activated killer cells: in vitro studies.
    Di Raimondo F; LaPushin R; Hersh EM
    Acta Haematol; 1987; 78 Suppl 1():77-83. PubMed ID: 3124452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell-mediated cytotoxicity.
    Ting CC; Hargrove ME; Yun YS
    J Immunol; 1988 Aug; 141(3):741-8. PubMed ID: 3260909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
    Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
    Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events.
    Trentin L; Ambrosetti A; Zambello R; Agostini C; Masciarelli M; Vinante F; Chilosi M; Pizzolo G; Cetto G; Semenzato G
    Leuk Res; 1987; 11(9):843-7. PubMed ID: 3499539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia.
    Foa R; Fierro MT; Lusso P; Bonferroni M; Raspadori D; Buzzi M; Zinzani PL; Resegotti L; Lauria F
    Leukemia; 1987 Apr; 1(4):377-9. PubMed ID: 3499543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine and natural killing regulation of growth of a hairy cell leukemia-like cell line: the role of interferon-alpha and interleukin-2.
    Reiter Z; Ozes ON; Blatt LM; Taylor MW
    J Immunother (1991); 1992 Jan; 11(1):40-9. PubMed ID: 1734947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
    Furbert-Harris PM; Evans CH
    Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis.
    Cordingley FT; Hoffbrand AV; Brenner MK
    Br J Haematol; 1988 Sep; 70(1):37-41. PubMed ID: 3140887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
    Reiter Z; Tomson S; Ozes ON; Taylor MW
    Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.